Mahkam Zanganeh - 11 Dec 2023 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Role
Chief Executive Officer, Director
Signature
/s/ Mahkam Zanganeh
Issuer symbol
SMMT
Transactions as of
11 Dec 2023
Net transactions value
+$1,214,458
Form type
4
Filing time
13 Dec 2023, 17:11:56 UTC
Previous filing
15 Nov 2023
Next filing
27 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SMMT Common Stock Exercise of in-the-money or at-the-money derivative security $705,332 +489,814 $1.44 489,814 11 Dec 2023 Direct F1
transaction SMMT Common Stock Purchase $10,350 +5,000 +1% $2.07 494,814 12 Dec 2023 Direct F2
transaction SMMT Common Stock Exercise of in-the-money or at-the-money derivative security $498,776 +315,681 +1.3% $1.58 24,889,479 11 Dec 2023 By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SMMT Warrant (right to buy) Exercise of in-the-money or at-the-money derivative security $0 -489,814 -100% $0.000000* 0 11 Dec 2023 Common Stock 489,814 $1.44 Direct F1
transaction SMMT Warrant (right to buy) Exercise of in-the-money or at-the-money derivative security $0 -315,681 -100% $0.000000* 0 11 Dec 2023 Common Stock 315,681 $1.58 By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person exercised certain warrants to purchase shares of common stock in accordance with the terms of such warrants.
F2 The Reporting Person purchased these shares in a single transaction on the open market.
F3 The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.